Evidence map›Paper›PMID 30841655›Full record

Trial reportInternational journal of environmental research and public health2019

Short-Term Consumption of Cuban Policosanol Lowers Aortic and Peripheral Blood Pressure and Ameliorates Serum Lipid Parameters in Healthy Korean Participants: Randomized, Double-Blinded, and Placebo-Controlled Study.

Hye-Jeong Park, Dhananjay Yadav, Da-Jeong Jeong, Suk-Jeong Kim, Myung-Ae Bae, Jae-Ryong Kim, Kyung-Hyun Cho

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of environmental research and public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Combination of Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2026
    Article
  6. Article
  7. Article
  8. Comparison of the In Vivo Efficacy of Cuban (RaydelPharmaceuticals (Basel, Switzerland) · 2024
    Article
  9. Article
  10. Cuban Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2024
    Article
  11. Review
  12. Combination Therapy of Cuban Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2024
    Article
  13. Article
  14. Consumption of Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Improving Effect of the Policosanol fromFoods (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hye-Jeong ParkResearch Institute of Protein Sensor, Yeungnam University, Gyeongsan 712-749, Korea. hjgod6867@ynu.ac.kr.
Dhananjay YadavDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 712-749, Korea. dhanyadav16481@gmail.com.ORCID 0000-0003-4047-7236
Da-Jeong JeongResearch Institute of Protein Sensor, Yeungnam University, Gyeongsan 712-749, Korea. qpslquf@ynu.ac.kr.
Suk-Jeong KimResearch Institute of Protein Sensor, Yeungnam University, Gyeongsan 712-749, Korea. superiorgene@ynu.ac.kr.
Myung-Ae BaeDrug Discovery Platform Technology Team, Korea Research Institute of Chemical Technology, Taejon 305-343, Korea. mbae@krict.re.kr.
Jae-Ryong KimDepartment of Biochemistry and Molecular Biology, Smart-Aging Convergence Research Center, College of Medicine, Yeungnam University, Daegu 705-717, Korea. kimjr@med.yu.ac.kr.
Kyung-Hyun ChoResearch Institute of Protein Sensor, Yeungnam University, Gyeongsan 712-749, Korea. chok@yu.ac.kr.ORCID 0000-0003-1198-4140
Yeungnam University · KRKorea Research Institute of Chemical Technology · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study was designed to investigate the short-term effects of policosanol consumption on blood pressure (BP) and the lipid parameters in healthy Korean participants with prehypertension. A total of 84 healthy participants were randomly allocated to three groups receiving placebo, 10 mg of policosanol, or 20 mg of policosanol for 12 weeks. Based on an average of three measurements of peripheral BP, the policosanol 20 mg group exhibited the most significant reduction, that is, up to 7.7% reduction of average systolic BP (SBP) from 136.3 ± 6.1 mmHg (week 0) to 125.9 ± 8.6 mmHg (week 12,

Indexed as

AdultAgedAnticholesteremic AgentsAntihypertensive AgentsAsian PeopleBlood PressureDouble-Blind MethodFatty AlcoholsFemaleHumansLipidsMaleMiddle AgedYoung AdultAnticholesteremic AgentsAntihypertensive AgentsFatty AlcoholsLipidspolicosanolblood pressurehigh-density lipoproteinslow-density lipoproteinspolicosanol

Identifiers

PMID30841655
PMCPMC6427682
OpenAlexW2919620293

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.